Lee’s Pharmaceutical Holdings Ltd

Lee's Pharmaceutical Holdings Limited is an investment holding company that develops, manufactures, markets, and sells pharmaceutical products in the People's Republic of China, Hong Kong, and internationally. It focuses on disease areas including cardiovascular, women's health, pediatrics, rare diseases, oncology, dermatology, and obstetrics. The company operates through two segments: Proprietary and Generic Products, and Licensed-In Products. Its Proprietary and Generic Products segment includes Nadroparin Calcium injection and Livaracine for blood clots and deep vein thrombosis, Yallaferon for viral infection, Slounase for hemostasis, Socazolimab Injection for recurrent or metastatic cervical cancer, Treprostinil injection for pulmonary arterial hypertension, fondaparinux sodium injection for deep vein thrombosis, Sodium Phenylbutyrate Granules for urea cycle disorders, Apremilast Tablets for plaque psoriasis, and Azilsartan Tablets for hypertension. The Licensed-In Products segment offers Sancuso for chemotherapy-induced nausea and vomiting, Bredinin for immunosuppression in renal transplantation, Centraxal Plus for acute otitis media with tympanostomy tubes, Ferplex for iron deficiency anemia, Intrarosa for vulvovaginal atrophy, Adasuve for agitation associated with schizophrenia or bipolar I disorder in adults, Mictonorm for urinary incontinence, Natulan for Stage III and IV Hodgkin's disease, Lutrate for prostate cancer, Nitric Oxide for Inhalation for hypoxic respiratory failure associated with pulmonary hypertension, Omacor for omega-3-acid ethyl esters, Zanidip for hypertension, Readyfusor for post-operative pain management, Teglutik for amyotrophic lateral sclerosis, Trittico for insomnia/depression, Dicoflor and VSL#3 for probiotics, and Zingo for topical local analgesics. Founded in 1994, the company is headquartered in Sha Tin, Hong Kong.